| |
| |
|
| Insider
Information: |
Scangos George A |
| Relationship: |
Director |
| City: |
South San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
937,662 |
|
|
Indirect Shares
|
3,762,360 |
|
|
| Direct
Value |
$29,946,005 |
|
|
|
Indirect Value
|
$5,005,151 |
|
|
| Total
Shares |
4,700,022 |
|
|
| Total
Value |
$34,951,156 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Exelixis Inc |
EXEL |
Director |
2020-05-18 |
714,717 |
2020-05-18 |
23,595 |
Premium* |
|
|
Anadys Pharmaceuticals Inc |
ANDS |
Director |
2008-08-26 |
33,188 |
2004-03-31 |
0 |
Premium* |
|
|
Biogen Idec Inc |
BIIB |
Chief Executive Office... |
2016-07-21 |
54,779 |
2016-07-21 |
10,756 |
Premium* |
|
|
Agilent Technologies Inc |
A |
Director |
2024-03-15 |
21,989 |
2024-03-15 |
14,450 |
Premium* |
|
|
Vir Biotechnology, Inc. |
VIR |
Director |
2024-02-26 |
112,989 |
2024-02-26 |
3,713,559 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-09-15 |
4 |
D |
$0.00 |
$0 |
I/I |
(5,377,590) |
0 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-10-17 |
4 |
A |
$0.00 |
$0 |
I/I |
3,500,000 |
1,750,000 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
D/D |
1,750,000 |
1,918,489 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-09-15 |
4 |
A |
$0.00 |
$0 |
I/I |
1,750,000 |
1,750,000 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-10-17 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,750,000) |
0 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
Director |
– • – |
2023-10-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,750,000) |
168,489 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2016-12-05 |
4 |
OE |
$8.99 |
$3,218,204 |
D/D |
357,976 |
1,668,186 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
President and CEO |
• • – |
2020-04-14 |
4 |
A |
$29.56 |
$6,999,985 |
D/D |
236,806 |
4,713,559 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
President and CEO |
• • – |
2020-04-14 |
4 |
D |
$29.56 |
$6,999,985 |
I/I |
(236,806) |
1,907,329 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2016-12-05 |
4 |
S |
$17.81 |
$3,646,028 |
D/D |
(204,718) |
1,463,468 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
President and CEO |
• • – |
2021-02-16 |
4 |
A |
$0.00 |
$0 |
D/D |
111,000 |
4,609,559 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
President and CEO |
• • – |
2022-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
111,000 |
223,989 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2018-08-10 |
4 |
OE |
$4.42 |
$525,332 |
D/D |
108,333 |
1,586,981 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-04-23 |
4 |
AS |
$25.68 |
$2,598,635 |
D/D |
(100,000) |
753,031 |
0 |
% |
|
| VIR |
Vir Biotechnology, Inc. |
President and CEO |
• • – |
2022-12-21 |
4 |
A |
$0.00 |
$0 |
I/I |
99,968 |
111,644 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
President and CEO |
• • – |
2022-12-21 |
4 |
AS |
$0.00 |
$0 |
I/I |
(99,968) |
827,151 |
0 |
- |
|
| EXEL |
Exelixis Inc |
President, CEO & Director |
• • – |
2003-10-09 |
4 |
S |
$7.80 |
$601,536 |
D/D |
(77,120) |
1,719,841 |
|
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-05-18 |
4 |
AS |
$25.96 |
$1,947,000 |
D/D |
(75,000) |
714,717 |
0 |
% |
|
| VIR |
Vir Biotechnology, Inc. |
President and CEO |
• • – |
2023-01-18 |
4 |
AS |
$0.00 |
$0 |
I/I |
(64,930) |
3,533,629 |
0 |
- |
|
| VIR |
Vir Biotechnology, Inc. |
President and CEO |
• • – |
2023-01-18 |
4 |
A |
$0.00 |
$0 |
I/I |
64,930 |
179,930 |
0 |
- |
|
| BIIB |
Biogen Idec Inc |
Chief Executive Officer |
• • – |
2010-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
63,165 |
63,165 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-05-15 |
4 |
OE |
$4.58 |
$263,613 |
D/D |
51,686 |
789,717 |
0 |
- |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-02-18 |
4 |
AS |
$20.73 |
$1,036,500 |
D/D |
(50,000) |
963,031 |
0 |
% |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2020-04-20 |
4 |
AS |
$23.39 |
$1,194,637 |
D/D |
(50,000) |
863,031 |
0 |
% |
|
| EXEL |
Exelixis Inc |
Director |
– • – |
2018-12-03 |
4 |
AS |
$21.16 |
$846,400 |
D/D |
(40,000) |
1,456,981 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
